Oncology & Cancer

FDA: Cyramza approval now includes non-small-cell lung CA

(HealthDay)—U.S. Food and Drug Administration approval of the anti-cancer drug Cyramza (ramucirumab) has been expanded to include aggressive non-small-cell lung cancer (NSCLC), the agency said Friday.

Oncology & Cancer

New HPV vaccine strengthens cancer protection

The drugmaker Merck & Co. Inc. has received approval for an updated version of its Gardasil vaccine that protects against an additional five strains of the virus that causes most cases of cervical cancer.

Health

Dead teen's parents seek ban on caffeine powder

The parents of an Ohio teen who died from an overdose of caffeine powder are urging federal regulators to ban sales of the stimulant, saying that children must be protected from a highly potent substance.

page 14 from 40